<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00626834</url>
  </required_header>
  <id_info>
    <org_study_id>OV-1014</org_study_id>
    <nct_id>NCT00626834</nct_id>
  </id_info>
  <brief_title>Vigabatrin Ph 1 Cocaine Interaction Study</brief_title>
  <official_title>A Phase 1 Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Intravenous Cocaine and Oral Gamma Vinyl-Gamma-Amino Butyric Acid (VIGABATRIN) Interaction Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institute on Drug Abuse (NIDA)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1 safety/tolerably study to determine if there are clinically significant
      interactions between oral vigabatrin (gamma vinyl-gamma-amino butyric acid; VGB) concurrent
      with intravenous (IV) cocaine infusions.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      STUDY DESIGN: This is a randomized, double-blind, placebo-controlled, parallel group study of
      the effects of VGB compared to placebo control on the physiological and subjective effects of
      IV infusions of cocaine (cocaine experienced volunteers).

      Subjects will be randomized within each clinical site to one of four groups (placebo control
      or one of three doses of VGB twice daily).During VGB steady state dosing, subjects will
      receive double-blind infusions of saline and cocaine. Subjects will be asked to return for
      follow-up approximately 7 and 14 days after the day of clinic discharge.

      STUDY DURATION: The maximum duration is 56 days, including 14 inpatient days of assessments
      and investigational products administration, and two follow-up visits after clinic discharge.

      SAMPLE SIZE: Twenty-four subjects will be randomized to one of three doses of vigabatrin or
      placebo.

      POPULATION: Volunteer, cocaine-experienced, non-treatment seeking cocaine users, 18 to 45
      years of age.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2008</start_date>
  <completion_date type="Actual">October 2010</completion_date>
  <primary_completion_date type="Actual">October 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>safety/tolerability and AE assessments including HR/BP/ECG/QTc</measure>
    <time_frame>56 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>VGB/PK during cocaine infusions and effect of VGB on cocaine craving</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Cocaine Addiction</condition>
  <arm_group>
    <arm_group_label>Vigabatrin Dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Vigabatrin Dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Vigabatrin Dose 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Matching placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vigabatrin</intervention_name>
    <description>Dose 1 BID</description>
    <arm_group_label>Vigabatrin Dose 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vigabatrin</intervention_name>
    <description>Dose 2 BID</description>
    <arm_group_label>Vigabatrin Dose 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vigabatrin</intervention_name>
    <description>Dose 3 BID</description>
    <arm_group_label>Vigabatrin Dose 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Matching placebo</intervention_name>
    <description>Matching placebo BID</description>
    <arm_group_label>Matching placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Be between 18 and 45 years of age, inclusive

          -  Currently be a non-treatment seeking cocaine user as confirmed by a positive urine
             test for cocaine

          -  Able to provide written informed consent

          -  A negative pregnancy test within 72 hours prior to receiving the first infusion of
             cocaine

        Exclusion Criteria:

        Please contact site for more information.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John D. Roache, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Texas</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nora Chiang, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Institute on Drug Abuse (NIDA)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ahmed Elkashef, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Institute on Drug Abuse (NIDA)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Roberta Kahn, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Institute on Drug Abuse (NIDA)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Texas Health Science Center</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 18, 2008</study_first_submitted>
  <study_first_submitted_qc>February 28, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 29, 2008</study_first_posted>
  <last_update_submitted>January 11, 2017</last_update_submitted>
  <last_update_submitted_qc>January 11, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cocaine addiction</keyword>
  <keyword>vigabatrin</keyword>
  <keyword>ovation pharmaceuticals</keyword>
  <keyword>cocaine</keyword>
  <keyword>cocaine related disorders</keyword>
  <keyword>behavior addictive</keyword>
  <keyword>mental disorders</keyword>
  <keyword>therapeutic uses</keyword>
  <keyword>physiologic effects of drugs</keyword>
  <keyword>disorder of environmental origin</keyword>
  <keyword>central nervous system stimulants</keyword>
  <keyword>central nervous system agents</keyword>
  <keyword>pharmacological actions</keyword>
  <keyword>substance related disorders</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Behavior, Addictive</mesh_term>
    <mesh_term>Cocaine-Related Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cocaine</mesh_term>
    <mesh_term>Vigabatrin</mesh_term>
    <mesh_term>Central Nervous System Stimulants</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

